Trial Profile
Impact of Neutralizing Antibodies on Interferon Responsive Genes Highlights Biomarker Response.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Interferon beta-1a (Primary) ; Interferon beta-1a (Primary) ; Interferon beta-1b
- Indications Multiple sclerosis
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- Sponsors Biogen Idec
- 27 Oct 2009 New trial record